Correlation between RPPA expression and clinical features
Testicular Germ Cell Tumors (Primary solid tumor)
02 April 2015  |  analyses__2015_04_02
Maintainer Information
Citation Information
Maintained by Juok Cho (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2015): Correlation between RPPA expression and clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1PC31HB
Overview
Introduction

This pipeline uses various statistical tests to identify RPPAs whose expression levels correlated to selected clinical features.

Summary

Testing the association between 201 genes and 8 clinical features across 103 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 4 clinical features related to at least one genes.

  • 30 genes correlated to 'YEARS_TO_BIRTH'.

    • GSK3A GSK3B|GSK3-ALPHA-BETA-M-V ,  SFRS1|SF2-M-V ,  PREX1|PREX1-R-E ,  NA|SMAC-M-QC ,  GAB2|GAB2-R-V ,  ...

  • 30 genes correlated to 'NEOPLASM_DISEASESTAGE'.

    • CCNE2|CYCLIN_E2-R-C ,  PEA15|PEA15-R-V ,  MS4A1|CD20-R-C ,  SFRS1|SF2-M-V ,  PDK1|PDK1-R-V ,  ...

  • 12 genes correlated to 'PATHOLOGY_T_STAGE'.

    • BCL2L1|BCL-XL-R-V ,  NRAS|N-RAS-M-V ,  PEA15|PEA15-R-V ,  SERPINE1|PAI-1-M-E ,  ACVRL1|ACVRL1-R-C ,  ...

  • 23 genes correlated to 'PATHOLOGY_N_STAGE'.

    • SFRS1|SF2-M-V ,  MAP2K1|MEK1-R-V ,  PDK1|PDK1_PS241-R-V ,  NRAS|N-RAS-M-V ,  PEA15|PEA15-R-V ,  ...

  • No genes correlated to 'DAYS_TO_DEATH_OR_LAST_FUP', 'PATHOLOGY_M_STAGE', 'RACE', and 'ETHNICITY'.

Results
Overview of the results

Complete statistical result table is provided in Supplement Table 1

Table 1.  Get Full Table This table shows the clinical features, statistical methods used, and the number of genes that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.

Clinical feature Statistical test Significant genes Associated with                 Associated with
DAYS_TO_DEATH_OR_LAST_FUP Cox regression test   N=0        
YEARS_TO_BIRTH Spearman correlation test N=30 older N=17 younger N=13
NEOPLASM_DISEASESTAGE Kruskal-Wallis test N=30        
PATHOLOGY_T_STAGE Spearman correlation test N=12 higher stage N=8 lower stage N=4
PATHOLOGY_N_STAGE Spearman correlation test N=23 higher stage N=12 lower stage N=11
PATHOLOGY_M_STAGE Wilcoxon test   N=0        
RACE Kruskal-Wallis test   N=0        
ETHNICITY Wilcoxon test   N=0        
Clinical variable #1: 'DAYS_TO_DEATH_OR_LAST_FUP'

No gene related to 'DAYS_TO_DEATH_OR_LAST_FUP'.

Table S1.  Basic characteristics of clinical feature: 'DAYS_TO_DEATH_OR_LAST_FUP'

DAYS_TO_DEATH_OR_LAST_FUP Duration (Months) 0.1-229.2 (median=41.6)
  censored N = 99
  death N = 3
     
  Significant markers N = 0
Clinical variable #2: 'YEARS_TO_BIRTH'

30 genes related to 'YEARS_TO_BIRTH'.

Table S2.  Basic characteristics of clinical feature: 'YEARS_TO_BIRTH'

YEARS_TO_BIRTH Mean (SD) 31.96 (9)
  Significant markers N = 30
  pos. correlated 17
  neg. correlated 13
List of top 10 genes differentially expressed by 'YEARS_TO_BIRTH'

Table S3.  Get Full Table List of top 10 genes significantly correlated to 'YEARS_TO_BIRTH' by Spearman correlation test

SpearmanCorr corrP Q
GSK3A GSK3B|GSK3-ALPHA-BETA-M-V 0.3529 0.0002561 0.026
SFRS1|SF2-M-V 0.3499 0.0002907 0.026
PREX1|PREX1-R-E 0.3352 0.0005373 0.026
NA|SMAC-M-QC 0.3331 0.0005869 0.026
GAB2|GAB2-R-V 0.3286 0.0007013 0.026
ERRFI1|MIG-6-M-V -0.3261 0.0007758 0.026
FN1|FIBRONECTIN-R-V -0.3057 0.001689 0.0458
ERBB2|HER2-M-V -0.3036 0.001822 0.0458
YBX1|YB-1_PS102-R-V -0.2902 0.002948 0.0658
WWTR1|TAZ-R-V -0.2777 0.004507 0.0867
Clinical variable #3: 'NEOPLASM_DISEASESTAGE'

30 genes related to 'NEOPLASM_DISEASESTAGE'.

Table S4.  Basic characteristics of clinical feature: 'NEOPLASM_DISEASESTAGE'

NEOPLASM_DISEASESTAGE Labels N
  STAGE I 14
  STAGE IA 20
  STAGE IB 8
  STAGE II 5
  STAGE IIA 3
  STAGE IIC 1
  STAGE III 1
  STAGE IIIA 1
  STAGE IIIB 5
  STAGE IIIC 4
  STAGE IS 38
     
  Significant markers N = 30
List of top 10 genes differentially expressed by 'NEOPLASM_DISEASESTAGE'

Table S5.  Get Full Table List of top 10 genes differentially expressed by 'NEOPLASM_DISEASESTAGE'

kruskal_wallis_P Q
CCNE2|CYCLIN_E2-R-C 9.53e-05 0.0192
PEA15|PEA15-R-V 0.000579 0.0582
MS4A1|CD20-R-C 0.001959 0.128
SFRS1|SF2-M-V 0.002686 0.128
PDK1|PDK1-R-V 0.004356 0.128
SCD1|SCD1-M-V 0.004463 0.128
PDK1|PDK1_PS241-R-V 0.004885 0.128
MAPK9|JNK2-R-C 0.005098 0.128
GAB2|GAB2-R-V 0.006276 0.14
MAPK14|P38-R-V 0.008393 0.16
Clinical variable #4: 'PATHOLOGY_T_STAGE'

12 genes related to 'PATHOLOGY_T_STAGE'.

Table S6.  Basic characteristics of clinical feature: 'PATHOLOGY_T_STAGE'

PATHOLOGY_T_STAGE Mean (SD) 1.45 (0.56)
  N
  T1 60
  T2 40
  T3 3
     
  Significant markers N = 12
  pos. correlated 8
  neg. correlated 4
List of top 10 genes differentially expressed by 'PATHOLOGY_T_STAGE'

Table S7.  Get Full Table List of top 10 genes significantly correlated to 'PATHOLOGY_T_STAGE' by Spearman correlation test

SpearmanCorr corrP Q
BCL2L1|BCL-XL-R-V 0.3813 7.078e-05 0.0142
NRAS|N-RAS-M-V -0.3141 0.001233 0.124
PEA15|PEA15-R-V 0.297 0.002317 0.155
SERPINE1|PAI-1-M-E 0.2777 0.004504 0.211
ACVRL1|ACVRL1-R-C -0.2731 0.005259 0.211
CCNE2|CYCLIN_E2-R-C -0.2617 0.007578 0.23
YBX1|YB-1-R-V 0.2599 0.008009 0.23
MAPK9|JNK2-R-C 0.2505 0.0107 0.264
PCNA|PCNA-M-C 0.2439 0.01305 0.264
CLDN7|CLAUDIN-7-R-V 0.2431 0.01334 0.264
Clinical variable #5: 'PATHOLOGY_N_STAGE'

23 genes related to 'PATHOLOGY_N_STAGE'.

Table S8.  Basic characteristics of clinical feature: 'PATHOLOGY_N_STAGE'

PATHOLOGY_N_STAGE Mean (SD) 0.2 (0.46)
  N
  N0 40
  N1 8
  N2 1
     
  Significant markers N = 23
  pos. correlated 12
  neg. correlated 11
List of top 10 genes differentially expressed by 'PATHOLOGY_N_STAGE'

Table S9.  Get Full Table List of top 10 genes significantly correlated to 'PATHOLOGY_N_STAGE' by Spearman correlation test

SpearmanCorr corrP Q
SFRS1|SF2-M-V -0.4766 0.0005365 0.0918
MAP2K1|MEK1-R-V 0.4588 0.0009137 0.0918
PDK1|PDK1_PS241-R-V 0.432 0.00194 0.121
NRAS|N-RAS-M-V -0.4119 0.003274 0.121
PEA15|PEA15-R-V 0.4028 0.004111 0.121
TP53BP1|53BP1-R-E -0.4026 0.004134 0.121
SCD1|SCD1-M-V -0.4005 0.004347 0.121
PDK1|PDK1-R-V 0.3942 0.005074 0.121
CCNE2|CYCLIN_E2-R-C -0.3914 0.005416 0.121
MAPK9|JNK2-R-C 0.3789 0.007258 0.135
Clinical variable #6: 'PATHOLOGY_M_STAGE'

No gene related to 'PATHOLOGY_M_STAGE'.

Table S10.  Basic characteristics of clinical feature: 'PATHOLOGY_M_STAGE'

PATHOLOGY_M_STAGE Labels N
  class0 89
  class1 4
     
  Significant markers N = 0
Clinical variable #7: 'RACE'

No gene related to 'RACE'.

Table S11.  Basic characteristics of clinical feature: 'RACE'

RACE Labels N
  ASIAN 4
  BLACK OR AFRICAN AMERICAN 4
  WHITE 91
     
  Significant markers N = 0
Clinical variable #8: 'ETHNICITY'

No gene related to 'ETHNICITY'.

Table S12.  Basic characteristics of clinical feature: 'ETHNICITY'

ETHNICITY Labels N
  HISPANIC OR LATINO 9
  NOT HISPANIC OR LATINO 85
     
  Significant markers N = 0
Methods & Data
Input
  • Expresson data file = TGCT-TP.rppa.txt

  • Clinical data file = TGCT-TP.merged_data.txt

  • Number of patients = 103

  • Number of genes = 201

  • Number of clinical features = 8

Selected clinical features
  • For clinical features selected for this analysis and their value conozzle.versions, please find a documentation on selected CDEs .

  • Survival time data

    • Survival time data is a combined value of days_to_death and days_to_last_followup. For each patient, it creates a combined value 'days_to_death_or_last_fup' using conversion process below.

      • if 'vital_status'==1(dead), 'days_to_last_followup' is always NA. Thus, uses 'days_to_death' value for 'days_to_death_or_fup'

      • if 'vital_status'==0(alive),

        • if 'days_to_death'==NA & 'days_to_last_followup'!=NA, uses 'days_to_last_followup' value for 'days_to_death_or_fup'

        • if 'days_to_death'!=NA, excludes this case in survival analysis and report the case.

      • if 'vital_status'==NA,excludes this case in survival analysis and report the case.

    • cf. In certain diesase types such as SKCM, days_to_death parameter is replaced with time_from_specimen_dx or time_from_specimen_procurement_to_death .

  • This analysis excluded clinical variables that has only NA values.

Survival analysis

For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels

Correlation analysis

For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R

Wilcoxon rank sum test (Mann-Whitney U test)

For two groups (mutant or wild-type) of continuous type of clinical data, wilcoxon rank sum test (Mann and Whitney, 1947) was applied to compare their mean difference using 'wilcox.test(continuous.clinical ~ as.factor(group), exact=FALSE)' function in R. This test is equivalent to the Mann-Whitney test.

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Andersen and Gill, Cox's regression model for counting processes, a large sample study, Annals of Statistics 10(4):1100-1120 (1982)
[2] Spearman, C, The proof and measurement of association between two things, Amer. J. Psychol 15:72-101 (1904)
[3] Mann and Whitney, On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other, Annals of Mathematical Statistics 18 (1), 50-60 (1947)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)